New data from a phase III study of Pfizer Inc.'s tafamidis in treating the rare and fatal disorder transthyretin amyloid cardiomyopathy (ATTR-CM) showed a 30 percent reduction in the risk of mortality and 32 percent reduction in the rate of cardiovascular-related hospitalizations vs. placebo. The data, presented at the European Society of Cardiology Congress in Munich and simultaneously published online in The New England Journal of Medicine, are likely to lay the groundwork for an upcoming U.S. regulatory filing for the drug.